Abstract
We investigated the effect of platelet fibrinogen receptor blockade on infarct size after primary angioplasty. Abciximab significantly reduced the time-to-peak creatine kinase without affecting enzymatic infarct size, suggesting a beneficial effect on the pattern and speed of reperfusion.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Abciximab
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Coronary Angiography
-
Creatine Kinase / blood
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage*
-
Immunoglobulin Fab Fragments / adverse effects
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Myocardial Infarction / diagnosis
-
Myocardial Infarction / therapy*
-
Myocardial Reperfusion Injury / diagnosis
-
Myocardial Reperfusion Injury / therapy*
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Platelet Aggregation Inhibitors / adverse effects
-
Recurrence
-
Retreatment
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Creatine Kinase
-
Abciximab